NYSE · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · LARGE CAP
Cencora, Inc. COR
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY17 YEARS OF DIVIDEND GROWTH
Revenue · FY2025
$321.3B
▲ 9.3% vs FY2024
Dividend streak
17 yrs
Raised every year since 2009
EPS · FY25
$7.96
Dividend / sh · FY25
$2.20
Payout · FY25
28%
ROE · FY25
144.3%
Net margin · FY25
0.5%
Dividend coverage
3.6×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 321.3B
Revenue, FY2025 · full 19-year series below
Revenue
Net income
0 cents of every revenue dollar became profit this year.
Per share
USD 7.96
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 3.6 times — the rest stayed in the company.
Profitability
144.3%
Return on equity, FY2025
ROE
Operating margin0.8%
Net margin0.5%
Return on assets2.2%
Each USD of equity produced 144 cents of profit this year.
Returned to shareholders
USD 843.4M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 437.1M
Net buybacksUSD 406.3M
Share of profit54.3%
Consecutive raises17 years
USD 437.1M in dividends and USD 406.3M in buybacks — 54% of the year's profit went back to shareholders.
Growth
+11.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+10.4%
+11.1%
+9.0%
+9.9%
Net income
−2.9%
+6.1%
EPS, diluted
−0.3%
+8.9%
Dividend / share
+6.1%
+5.8%
+6.6%
+13.7%
Returned to shareholders
+2.6%
+3.9%
−8.8%
+4.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.19B
Shares outstanding, FY2025
Change, 5 years−5.0%
Change, 10 years−6.3%
The share count shrank 5% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 76.6B
total assets, end of FY2025
Total assetsUSD 76.6B
EquityUSD 1.5B
CashUSD 4.4B
Gross debtUSD 7.7B
Net debtUSD 3.3B
Current ratio0.90×
Net debt stands at 219% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
321.3
294.0
262.2
238.6
214.0
189.9
179.6
167.9
153.1
146.8
136.0
119.6
88.0
78.1
78.7
77.8
71.8
70.2
65.7
Operating income $B
2.6
2.2
2.3
2.4
2.4
−5.1
1.1
1.4
1.1
1.5
0.4
0.8
0.9
1.3
1.2
1.1
0.9
0.8
0.8
EBITDA $B
3.7
3.3
3.3
3.1
2.9
−4.7
1.6
1.9
1.5
1.9
0.7
1.0
1.1
1.4
1.3
1.2
1.0
0.9
0.9
Income tax $B
0.7
0.5
0.4
0.5
0.7
−1.9
0.1
−0.4
0.6
−0.0
0.4
0.4
0.3
0.5
0.4
0.4
0.3
0.3
0.3
Net income $B
1.6
1.5
1.7
1.7
1.5
−3.4
0.9
1.7
0.4
1.4
−0.1
0.3
0.4
0.7
0.7
0.6
0.5
0.3
0.5
EPS, diluted $
7.96
7.53
8.53
8.04
7.39
−16.65
4.04
7.53
1.64
6.32
−0.63
1.16
1.84
2.80
2.54
2.22
1.66
0.77
1.25
Dividend / sh $
2.20
2.04
1.94
1.84
1.76
1.66
1.60
1.52
1.46
1.36
1.16
0.94
0.84
0.52
0.43
0.32
0.21
0.15
·
Payout %
28
28
23
23
24
−10
40
20
88
20
−184
78
45
18
17
14
12
19
8
ROE %
144.3
258.4
1124.4
28805.8
·
−366.5
29.4
66.4
17.4
104.0
−10.8
12.9
18.2
27.0
24.3
22.5
18.6
8.6
15.1
Shares out B
0.19
0.19
0.20
0.21
0.21
0.20
0.21
0.21
0.22
0.22
0.21
0.22
0.23
0.24
0.26
0.28
0.29
0.31
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
74 of 74
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed